Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
1.365
USD
|
-3.19%
|
|
-12.50%
|
-48.30%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
365
|
378.8
|
359.2
|
122.7
|
119.1
|
66.4
|
-
|
-
|
Enterprise Value (EV)
1 |
365
|
293.9
|
294.8
|
122.7
|
119.1
|
66.4
|
66.4
|
66.4
|
P/E ratio
|
-9.56
x
|
-8.02
x
|
-8.02
x
|
-1.91
x
|
-2.38
x
|
-1.32
x
|
-1.36
x
|
-1.43
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
106
x
|
120
x
|
24
x
|
98.5
x
|
21.7
x
|
7.37
x
|
4.22
x
|
3.39
x
|
EV / Revenue
|
106
x
|
120
x
|
24
x
|
98.5
x
|
21.7
x
|
7.37
x
|
4.22
x
|
3.39
x
|
EV / EBITDA
|
-
|
-8,611,598
x
|
-8,461,223
x
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-11,447,277
x
|
-9,036,839
x
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-0%
|
-0%
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
22,994
|
30,278
|
31,761
|
43,043
|
45,123
|
48,643
|
-
|
-
|
Reference price
2 |
15.88
|
12.51
|
11.31
|
2.850
|
2.640
|
1.365
|
1.365
|
1.365
|
Announcement Date
|
3/12/20
|
3/9/21
|
3/16/22
|
3/21/23
|
3/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
3.458
|
3.154
|
14.94
|
1.245
|
5.49
|
9.006
|
15.73
|
19.57
|
EBITDA
|
-
|
-43.99
|
-42.45
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-36.77
|
-45.04
|
-43.71
|
-53.22
|
-52.15
|
-58.27
|
-69.92
|
-80.78
|
Operating Margin
|
-1,063.21%
|
-1,427.96%
|
-292.56%
|
-4,274.3%
|
-949.89%
|
-647.05%
|
-444.46%
|
-412.75%
|
Earnings before Tax (EBT)
1 |
-36.29
|
-44.58
|
-43.67
|
-53.01
|
-50.73
|
-57.28
|
-68.86
|
-79.36
|
Net income
1 |
-36.7
|
-44.78
|
-44.16
|
-53.01
|
-50.73
|
-57.28
|
-68.12
|
-76.79
|
Net margin
|
-1,061.18%
|
-1,419.79%
|
-295.56%
|
-4,257.08%
|
-924.1%
|
-636.06%
|
-433.07%
|
-392.35%
|
EPS
2 |
-1.660
|
-1.560
|
-1.410
|
-1.490
|
-1.110
|
-1.032
|
-1.004
|
-0.9575
|
Free Cash Flow
|
-
|
-33.09
|
-39.75
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-1,049.01%
|
-266.04%
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/12/20
|
3/9/21
|
3/16/22
|
3/21/23
|
3/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
2.395
|
8.254
|
1
|
0.026
|
0.068
|
0.1512
|
0.187
|
1.382
|
2.1
|
1.821
|
1.213
|
1.272
|
1.277
|
5.243
|
1
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-13.02
|
-7.893
|
-14.24
|
-13.09
|
-11.03
|
-14.87
|
-13.38
|
-13.52
|
-11.42
|
-13.83
|
-13.99
|
-14.93
|
-16.02
|
-13.32
|
-20.5
|
Operating Margin
|
-543.55%
|
-95.62%
|
-1,423.8%
|
-50,346.15%
|
-16,222.06%
|
-9,829.93%
|
-7,155.08%
|
-978.08%
|
-543.76%
|
-759.58%
|
-1,153.37%
|
-1,173.35%
|
-1,254.06%
|
-253.97%
|
-2,050%
|
Earnings before Tax (EBT)
1 |
-12.99
|
-7.889
|
-14.26
|
-13.21
|
-10.96
|
-14.59
|
-13.11
|
-13.18
|
-11
|
-13.43
|
-13.79
|
-14.74
|
-15.73
|
-13.14
|
-20.55
|
Net income
1 |
-12.99
|
-8.384
|
-14.26
|
-13.21
|
-10.96
|
-14.59
|
-13.11
|
-13.18
|
-11
|
-13.43
|
-13.79
|
-14.74
|
-15.73
|
-13.14
|
-20.55
|
Net margin
|
-542.51%
|
-101.57%
|
-1,425.5%
|
-50,800%
|
-16,110.29%
|
-9,649.13%
|
-7,010.16%
|
-954.05%
|
-524.05%
|
-737.73%
|
-1,136.78%
|
-1,158.92%
|
-1,231.98%
|
-250.62%
|
-2,055%
|
EPS
2 |
-0.4100
|
-0.2500
|
-0.4400
|
-0.3700
|
-0.3100
|
-0.3800
|
-0.2900
|
-0.2900
|
-0.2400
|
-0.2900
|
-0.2820
|
-0.2740
|
-0.2620
|
-0.2280
|
-0.4100
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/9/21
|
3/16/22
|
5/10/22
|
8/4/22
|
11/14/22
|
3/21/23
|
5/9/23
|
8/8/23
|
11/3/23
|
3/28/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
84.9
|
64.4
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-33.1
|
-39.8
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
0.05
|
-
|
0.91
|
-
|
-
|
1.34
|
1.79
|
2.22
|
Capex / Sales
|
1.34%
|
-
|
6.11%
|
-
|
-
|
14.87%
|
11.39%
|
11.33%
|
Announcement Date
|
3/12/20
|
3/9/21
|
3/16/22
|
3/21/23
|
3/28/24
|
-
|
-
|
-
|
Last Close Price
1.365
USD Average target price
9.4
USD Spread / Average Target +588.64% Consensus |
1st Jan change
|
Capi.
|
---|
| -48.30% | 66.4M | | -2.31% | 103B | | +0.56% | 95.28B | | +1.69% | 22.15B | | -17.37% | 21.02B | | -9.30% | 18.15B | | -41.01% | 16.74B | | -14.85% | 16.05B | | +3.21% | 13.68B | | +33.54% | 12.17B |
Bio Therapeutic Drugs
|